Overview
Cat #:
STC-040
Alternative Name Alpha-Ctx MII, Alpha-MII, α-Conotoxin MII
Lyophilized Powder yes
Origin Conus magus
Source Synthetic peptide
MW: 1711 Da
Purity: >98%
Form Lyophilized Powder
Effective concentration 5 – 20 nM
Sequence GCCSNPVCHLEHSNLC – NH2
Modifications Cys16 – C-terminal amide
Disulfide bonds location- Cys2-Cys8, Cys3-Cys16
Molecular formula C67H103N22O23S4
CAS No.: 175735-93-0
PubChem CID 57340508
Activity A potent antagonist of nAChRs composed of α3β2 and α6β2 subunits1,2. Also, potently blocks β3-containing neuronal nicotinic receptors3.
Shipping and storage Shipped at room temperature. Product as supplied can be stored intact at room temperature for several weeks. For longer periods, it should be stored at -20°C. Protect from light and moisture.
Solubility Soluble in water. It is recommended to prepare fresh solutions in working buffers before use, or aliquot stock solutions reconstituted in distilled water and keep at -20°C. Upon use, dilute the stock solution in the desired working buffer. Prevent repeated thawing and freezing cycles. Centrifuge all product preparations before use (10,000 g for 5 min).
Storage of solutions Store up to one week at 4°C or up to 6 months at -20°C.
Scientific background α-conotoxin MII is a 16 amino acid peptidyl toxin originally isolated from the venom of the marine snail, Conus magus1. This toxin was initially thought to be a selective antagonist for α3β2 nicotinic acetylcholine receptors (nAChRs)1. Subsequently, it has been shown that α-conotoxin MII is also an α6β2* nAChR subtype selective antagonist2 and it potently blocks β3-containing neuronal nAChRs3.
Neuronal nAChRs are a heterogeneous family of ligand-gated cation channels that are expressed throughout the brain and involved in a wide range of physiological and pathophysiological processes. These different receptor subtypes have a pentameric structure consisting of the homomeric or heteromeric combination of 12 different subunits (α2–α10, β2–β4)4.
nAChRs are critically important for neuronal survival and cognitive function, as well as regulation of neurodegenerative diseases, including Alzheimer’s and Parkinson’s. The nAChR subtypes share a common basic structure, but their biophysical and pharmacological properties depend on their subunit composition. Thus, the subunit makeup of the nAChR subtypes is central to understanding their function in the nervous system and for discovering new subtype-selective drugs4-6.
Target α3β2, α6β2 nAChRs
Peptide Content: 100%
Lyophilized Powder
For research purposes only, not for human use
Last Update: 02/01/2024
